Cite
HARVARD Citation
Catlett, I. et al. (2023). First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2. Clinical and translational science. 16 (1), pp. 151-164. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Catlett, I. et al. (2023). First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2. Clinical and translational science. 16 (1), pp. 151-164. [Online].